<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 获取免费报告) 的股价在周一的交易中跌破了其 200 日移动平均线。该股票的 200 日移动平均线为 2.30 美元，最低交易价为 2.11 美元。Oramed Pharmaceuticals 的股票最后交易价为 2.12 美元，成交量为 21,385 股。</p>
<p>获取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>另外，华尔街 Zen 在 5 月 17 日的研究报告中将 Oramed Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。</p>
<p><strong>获取我们最新的 ORMP 股票报告</strong></p>
<h2>Oramed Pharmaceuticals 股票表现</h2>
<p>该股票的 50 日移动平均线为 2.21 美元，200 日移动平均线为 2.30 美元。该股票的市值为 8660 万美元，市盈率为 19.27，贝塔值为 1.65。</p>
<p>Oramed Pharmaceuticals (NASDAQ:ORMP - 获取免费报告) 最近在 5 月 15 日发布了其财报。这家生物技术公司报告本季度每股收益（EPS）为-0.19 美元，低于分析师一致预期的-0.03 美元，差距为-0.16 美元。该公司本季度的收入为 200 万美元。股票研究分析师预测 Oramed Pharmaceuticals Inc.将在本年度发布-0.03 的每股收益。</p>
<h2>对 Oramed Pharmaceuticals 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近对其在 ORMP 的持仓进行了调整。BML Capital Management LLC 在第一季度将其在 Oramed Pharmaceuticals 的持仓增加了 14.3%。BML Capital Management LLC 目前拥有 3020748 股该生物技术公司的股票，价值 6464000 美元，此前在此期间又购买了 376841 股。Boothbay Fund Management LLC 在第四季度将其在 Oramed Pharmaceuticals 的持仓增加了 2.0%。Boothbay Fund Management LLC 目前拥有 845188 股该生物技术公司的股票，价值 2045000 美元，此前在此期间又购买了 16857 股。Peapod Lane Capital LLC 在第一季度将其在 Oramed Pharmaceuticals 的持仓增加了 11.0%。Peapod Lane Capital LLC 目前拥有 252224 股该生物技术公司的股票，价值 540000 美元，此前在此期间又购买了 24985 股。Dimensional Fund Advisors LP 在第四季度将其在 Oramed Pharmaceuticals 的持仓增加了 143.8%。Dimensional Fund Advisors LP 目前拥有 118995 股该生物技术公司的股票，价值 288000 美元，此前在此期间又购买了 70190 股。最后，Jane Street Group LLC 在第一季度将其在 Oramed Pharmaceuticals 的持仓增加了 35.3%。Jane Street Group LLC 目前拥有 67173 股该生物技术公司的股票，价值 144000 美元，此前在此期间又购买了 17510 股。12.73% 的股票由机构投资者持有。</p>
<h2>Oramed Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Oramed Pharmaceuticals Inc.从事用于治疗糖尿病的药物解决方案的研究与开发，以及用于口服摄入胶囊以递送多肽的研究。该公司的产品组合包括 ORMD-0801，一种口服胰岛素胶囊，目前正在进行针对糖尿病患者的第三阶段临床试验，以及针对非酒精性脂肪肝炎的第二阶段临床试验；以及 ORA-D-013-1 和 ORA-D-013-2，这两者已完成针对 2 型糖尿病的第二阶段临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Oramed Pharmaceuticals</li>
<li>百分比涨幅对投资者的启示及其未能传达的全部故事</li>
<li>Workday 股价暴跌：AI 投资者的自动买入机会</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>MercadoLibre 股价飙升——你应该等待更好的入场时机吗？</li>
<li>什么是日经 225 指数？</li>
<li>对市场有疑虑？三只股票帮助你度过恐惧、不确定性和怀疑</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Oramed Pharmaceuticals 吗？</h2>
<p>在考虑 Oramed Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，建议在更广泛的市场注意到之前购买……而 Oramed Pharmaceuticals 并不在名单上。</p>
<p>虽然 Oramed Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Oramed制药

<p>Oramed 制药（NASDAQ:ORMP）股票跌破其 200 日移动平均线 2.30 美元，当前交易价格为 2.12 美元，成交量为 21,385 股。该公司报告每股亏损 0.19 美元，低于预期 0.16 美元，季度收入为 200 万美元。分析师已将该股票评级从 “持有” 下调至 “卖出”。机构投资者持有该股票的 12.73%，多家对冲基金近期增加了其持仓。Oramed 专注于通过口服胰岛素胶囊和其他多肽递送方法治疗糖尿病</p>

<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.30 and traded as low as $2.11. Oramed Pharmaceuticals shares last traded at $2.12, with a volume of 21,385 shares trading hands.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 获取免费报告) 的股价在周一的交易中跌破了其 200 日移动平均线。该股票的 200 日移动平均线为 2.30 美元，最低交易价为 2.11 美元。Oramed Pharmaceuticals 的股票最后交易价为 2.12 美元，成交量为 21,385 股。</p>
</div><p>Get <strong>Oramed Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Wall Street Zen cut Oramed Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, May 17th.</p>
<div class="lb-trans"><p>另外，华尔街 Zen 在 5 月 17 日的研究报告中将 Oramed Pharmaceuticals 的评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Get Our Latest Stock Report on ORMP</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 ORMP 股票报告</strong></p>
</div><h2>Oramed Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 股票表现</h2>
</div><p>The stock's fifty day moving average is $2.21 and its 200 day moving average is $2.30. The stock has a market cap of $86.60 million, a P/E ratio of 19.27 and a beta of 1.65.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 2.21 美元，200 日移动平均线为 2.30 美元。该股票的市值为 8660 万美元，市盈率为 19.27，贝塔值为 1.65。</p>
</div><p>Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. Equities research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 EPS for the current year.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals (NASDAQ:ORMP - 获取免费报告) 最近在 5 月 15 日发布了其财报。这家生物技术公司报告本季度每股收益（EPS）为-0.19 美元，低于分析师一致预期的-0.03 美元，差距为-0.16 美元。该公司本季度的收入为 200 万美元。股票研究分析师预测 Oramed Pharmaceuticals Inc.将在本年度发布-0.03 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Oramed Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Oramed Pharmaceuticals 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in ORMP. BML Capital Management LLC raised its position in shares of Oramed Pharmaceuticals by 14.3% in the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock valued at $6,464,000 after purchasing an additional 376,841 shares during the period. Boothbay Fund Management LLC raised its position in shares of Oramed Pharmaceuticals by 2.0% in the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after purchasing an additional 16,857 shares during the period. Peapod Lane Capital LLC raised its position in shares of Oramed Pharmaceuticals by 11.0% in the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares during the period. 12.73% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对其在 ORMP 的持仓进行了调整。BML Capital Management LLC 在第一季度将其在 Oramed Pharmaceuticals 的持仓增加了 14.3%。BML Capital Management LLC 目前拥有 3020748 股该生物技术公司的股票，价值 6464000 美元，此前在此期间又购买了 376841 股。Boothbay Fund Management LLC 在第四季度将其在 Oramed Pharmaceuticals 的持仓增加了 2.0%。Boothbay Fund Management LLC 目前拥有 845188 股该生物技术公司的股票，价值 2045000 美元，此前在此期间又购买了 16857 股。Peapod Lane Capital LLC 在第一季度将其在 Oramed Pharmaceuticals 的持仓增加了 11.0%。Peapod Lane Capital LLC 目前拥有 252224 股该生物技术公司的股票，价值 540000 美元，此前在此期间又购买了 24985 股。Dimensional Fund Advisors LP 在第四季度将其在 Oramed Pharmaceuticals 的持仓增加了 143.8%。Dimensional Fund Advisors LP 目前拥有 118995 股该生物技术公司的股票，价值 288000 美元，此前在此期间又购买了 70190 股。最后，Jane Street Group LLC 在第一季度将其在 Oramed Pharmaceuticals 的持仓增加了 35.3%。Jane Street Group LLC 目前拥有 67173 股该生物技术公司的股票，价值 144000 美元，此前在此期间又购买了 17510 股。12.73% 的股票由机构投资者持有。</p>
</div><h2>Oramed Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc.从事用于治疗糖尿病的药物解决方案的研究与开发，以及用于口服摄入胶囊以递送多肽的研究。该公司的产品组合包括 ORMD-0801，一种口服胰岛素胶囊，目前正在进行针对糖尿病患者的第三阶段临床试验，以及针对非酒精性脂肪肝炎的第二阶段临床试验；以及 ORA-D-013-1 和 ORA-D-013-2，这两者已完成针对 2 型糖尿病的第二阶段临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Oramed Pharmaceuticals</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li>
<li>What is the Nikkei 225 index?</li>
<li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Oramed Pharmaceuticals</li>
<li>百分比涨幅对投资者的启示及其未能传达的全部故事</li>
<li>Workday 股价暴跌：AI 投资者的自动买入机会</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>MercadoLibre 股价飙升——你应该等待更好的入场时机吗？</li>
<li>什么是日经 225 指数？</li>
<li>对市场有疑虑？三只股票帮助你度过恐惧、不确定性和怀疑</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Oramed Pharmaceuticals 吗？</h2>
</div><p>Before you consider Oramed Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oramed Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，建议在更广泛的市场注意到之前购买……而 Oramed Pharmaceuticals 并不在名单上。</p>
</div><p>While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oramed Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Oramed 制药（NASDAQ:ORMP）的股票跌破了 200 日移动平均线 - 你应该卖出吗？